Blood-brain barrier permeability, inflammation, and clinical progression in Alzheimer's disease

niversity of Southampton0 个研究点目标入组 70 人开始时间: 2024年5月21日最近更新: 2024年6月3日

试验速览

暂无简介。

•1. Age > 50 years old, no upper limit.
•2. Able and willing to give informed consent for participation in the study at baseline.
•3. AD participants: meet international consensus criteria for a diagnosis of AD dementia or mild cognitive impairment secondary to AD.
•Control participants: no cognitive impairment and a MoCA score greater than, or equal to, 26 at baseline.

•1. Lack capacity to provide informed consent at baseline or decline to participate.
•2. Not proficient in English language.
•3. Absence of a reliable study partner (AD participants only).
•4. Diagnosis of mixed dementia or another central nervous system disease (e.g. multiple sclerosis, stroke).
•5. Intercurrent acute kidney injury, infection, or delirium.
•6. History or presence of major psychiatric disorder or alcohol/substance misuse, within the last two years.
•7. Diagnosis of any severe inflammatory disorder (e.g. rheumatoid arthritis, periodontitis, inflammatory bowel disease, chronic/recurrent gingivitis).
•8. Use of non-topical steroids or cytokine modulators.
•9. Previous brain imaging showing confluent white matter changes reflective of gross cerebrovascular disease.
•10. Impaired renal function that absolutely contraindicates contrast-enhanced MRI (eGFR < 40).
•11. Any contraindication for MRI (e.g. claustrophobia, implanted MR-unsafe metalwork, known hypersensitivity to contrast agent).

发起方

niversity of Southampton